复杂主动脉瘤开窗分支腔内修复术后1年瘤囊缩小与中期生存获益相关
本研究基于前瞻性非随机研究(2013—2022年)数据,纳入463例接受开窗分支腔内主动脉修复(FB-EVAR)的复杂腹主动脉瘤或胸腹主动脉瘤患者,按术后1年瘤囊直径变化分为缩小组(≥5 mm,270例)和未回缩组(<5 mm或扩张,193例)。中位随访38个月,校正混杂因素后未回缩组晚期死亡风险更高(校正HR 1.72,95%CI 1.18-2.52,P=.005),而主动脉相关死亡、破裂及二次干预两组相当。结论认为1年瘤囊缩小与生存改善相关。
要点
- FB-EVAR术后1年瘤囊缩小(≥5 mm)见于58%的患者,未回缩见于42%。
- 未回缩组校正后晚期死亡风险更高(校正HR 1.72,95%CI 1.18-2.52,P=.005)。
- 两组主动脉相关死亡、破裂及主动脉相关二次干预累积发生率相当。
核心结论
- FB-EVAR术后1年瘤囊缩小常见,且与患者生存改善相关;瘤囊扩张仅见于少数患者。
- 主动脉相关死亡和破裂发生率低,提示未回缩可能作为非主动脉相关死亡的替代标志物。
研究设计与样本
- 回顾性分析前瞻性非随机研究(2013—2022年)中接受FB-EVAR患者的临床数据。
- 纳入基线及术后6至18个月有连续随访CT扫描的患者463例(男性71%,平均年龄74±8岁)。
- 瘤囊直径变化定义为最大主动脉直径与基线中心线血流测量值的差值。
- 按瘤囊直径变化分为缩小组(≥5 mm)和未回缩组(<5 mm或扩张)。
- 主要终点为全因死亡率;次要终点为主动脉相关死亡、主动脉瘤破裂和主动脉相关二次干预。
主要发现
- 共549例患者接受FB-EVAR,其中463例有连续CT影像被纳入分析。
- 动脉瘤范围为胸腹主动脉瘤328例(71%),腹主动脉瘤135例(29%)。
- 瘤囊缩小270例(58%),未回缩193例(42%),其中1年时瘤囊扩张19例(4%)。
- 缩小组患者更年轻(73±8岁 vs 75±8岁;P<.001),其余心血管危险因素两组相似。
- 中位随访38个月(四分位距18-51个月);缩小组5年生存估计为69%±4.1%,未回缩组为46%±6.2%。
关键数值与推荐
- 瘤囊缩小定义为术后1年瘤囊直径较基线缩小≥5 mm。
- 未回缩定义为瘤囊直径变化<5 mm或扩张。
- 校正混杂因素包括年龄、慢性阻塞性肺疾病、慢性肾脏病、充血性心力衰竭和动脉瘤范围。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the impact of 1-year changes in aneurysm sac diameter on patient survival after fenestrated-branched endovascular aortic repair (FB-EVAR) of complex abdominal aortic aneurysms or thoracoabdominal aortic aneurysms. METHODS: We reviewed the clinical data of patients enrolled in a prospective nonrandomized study investigating FB-EVAR (2013-2022). Patients with sequential follow up computed tomography scans at baseline and 6 to 18 months after FB-EVAR were included in the analysis. Aneurysm sac diameter change was defined as the difference in maximum aortic diameter from baseline measurements obtained in centerline of flow. Patients were classified as those with sac shrinkage (≥5 mm) or failure to regress (<5 mm or expansion) according to sac diameter change. The primary end point was all-cause mortality. Secondary end points were aortic-related mortality (ARM), aortic aneurysm rupture (AAR), and aorta-related secondary intervention. RESULTS: There were 549 patients treated by FB-EVAR. Of these, 463 patients (71% male, mean age, 74 ± 8 years) with sequential computed tomography imaging were investigated. Aneurysm extent was thoracoabdominal aortic aneurysms in 328 patients (71%) and abdominal aortic aneurysms in 135 (29%). Sac shrinkage occurred in 270 patients (58%) and failure to regress in 193 patients (42%), including 19 patients (4%) with sac expansion at 1 year. Patients from both groups had similar cardiovascular risk factors, except for younger age among patients with sac shrinkage (73 ± 8 years vs 75 ± 8 years; P < .001). The median follow-up was 38 months (interquartile range, 18-51 months). The 5-year survival estimate was 69% ± 4.1% for the sac shrinkage group and 46% ± 6.2% for the failure to regress group. Survival estimates adjusted for confounders (age, chronic pulmonary obstructive disease, chronic kidney disease, congestive heart failure, and aneurysm extent) revealed a higher hazard of late mortality in patients with failure to regress (adjusted hazard ratio, 1.72; 95% confidence interval, 1.18-2.52; P = .005). The 5-year cumulative incidences of ARM (1.1% vs 3.1%; P = .30), AAR (0.6% vs 2.6%; P = .20), and aorta-related secondary intervention (17.0% ± 2.8% vs 19.0% ± 3.8%) were both comparable between the groups. CONCLUSIONS: Aneurysm sac shrinkage at 1 year is common after FB-EVAR and is associated with improved patient survival, whereas sac enlargement affects only a minority of patients. The low incidences of ARM and AAR indicate that failure to regress may serve as a surrogate marker for nonaortic-related death.
引用
- Mesnard T, Sulzer TAL, Kanamori LR, et al. Aneurysm sac shrinkage at 1 year after fenestrated-branched endovascular aortic repair of complex aortic aneurysms offers mid-term survival advantage. J Vasc Surg. 2024. PMID: 38825213. doi:10.1016/j.jvs.2024.05.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。